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Combination of phenethyl isothiocyanate (PEITC) and paclitaxel (taxol) has been shown to work synergistically to
increase apoptosis and cell cycle arrest in breast cancer cells. In this report, we further explored the mechanisms
for the synergistic activity of PEITC and taxol in MCF7 and MDA-MB-231 (MB) breast cancer cell lines. By Western
blotting analysis, treatment of MCF7 cells with both PEITC and taxol led to a 10.4-fold and 5.96-fold increase in
specific acetylation of alpha-tubulin over single agent PEITC and taxol, respectively. This synergistic effect on
acetylation of alpha-tubulin was also seen in MB cells. The combination of PEITC and taxol also reduced expressions
of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP
proteins. In conclusion, this study provided biochemical evidence for the mechanism of synergistic effect between
the epigenetic agent PEITC and the chemotherapeutic agent taxol.Introduction
Epigenetic modification of DNA and histone proteins
by methylation and deacetylation plays a key role in
carcinogenesis [1-5]. Methyltransferase inhibitors and
histone deacetylase (HDAC) inhibitors are novel anti-
cancer agents. Two DNA methyltransferase inhibitors,
azacitidine and decitabine, and two histone deacetylase
inhibitors, vorinostat and romidepsin, have been in clin-
ical use [6-12]. Belinostat was reported to induce durable
remission in refractory peripheral T-cell lymphoma [13].
Breast cancer is the most commonly diagnosed cancer
and the second leading cause of death among women.
Taxanes are a class of major chemotherapeutic agents
for breast cancer therapy. Paclitaxel (taxol) is a widely
used chemotherapy drug in the treatment of breast can-
cer and other solid tumors [14-16]. Taxol inhibits micro-
tubule disassembly when it binds to assembled tubulin,* Correspondence: jen-wei_chiao@nymc.edu; Delong_liu@nymc.edu
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stated.making the microtubules locked in polymerized state
[17]. Thus the taxol -exposed cells are in cell cycle arrest
[18-21]. Another effect of taxol is that it inhibits the
anti-apoptosis protein Bcl-2, and induces apoptosis in
cancer cells [22]. Even though taxol is a highly effective
anti-neoplastic agent, the toxicity of taxol, particularly at
a higher dosage, limits its prolonged use in patients
[15,23,24]. Further research is being done to increase
therapeutic efficacy and minimize toxicity. Radiation and
targeted therapy has been used effectively for breast can-
cer therapy [25-28]. Novel anti-cancer agents with novel
mechanisms of actions and new formulations are being
actively sought [29-31].
Phenethyl isothiocyanate (PEITC) belongs to the family
of isothiocyanates, which are initially found in a wide var-
iety of cruciferous vegetables. Natural ITCs are released
when the vegetables are cut or masticated. Phenethyl iso-
thiocyanate (PEITC) regulates epigenetic process. PEITC
has been shown to be a HDAC inhibitor in prostate
cancer, leukemia, and myeloma cells [32-35]. PEITC was
also shown to inhibit leukemia development in mice.
PEITC was shown to have dual functions and can induce
DNA hypomethylation as well as histone hyperacetylationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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of PEITC and taxol has synergistic inhibitory effects on
breast cancer cell growth [37]. The combination synergis-
tically increased apoptosis and cell cycle arrest in breast
cancer cells. In this report, we further explored the mecha-
nisms for the synergistic activity of PEITC and taxol.
Materials and methods
Chemicals and cell cultures
As described in previous reports [33-35], PEITC (phe-
nethyl isothiocyanate) was purchased from LKT Labs
and dissolved in 70% methanol and 30% deionized water
to a stock concentration of 10 mM. Paclitaxel (taxol)
powder (Sigma Chemical Co.) was dissolved in DMSO
and stored as a stock concentration of 200 nM.
Maintenance and culture of the MCF7 and MDA-MB-
231 (MB) cell lines were described in a prior report [37].
Briefly, the cells were seeded at 0.4 × 106 per ml and
0.2 × 106 per ml, respectively, of PRMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine
serum, 100 IU of penicillin/ml and 100 μg of strepto-
mycin/ml, and maintained at 37°C in a humidified at-
mosphere containing 5% CO2. At the specified time
points, the cells were harvested. Cell number and viabil-
ity were determined from at least triplicate cultures by
the trypan blue exclusion method.
Western blotting
MCF and MB cells were treated with PEITC and/or
paclitaxel at various concentrations for 48 hours. The
cell lysates were used for Western blot analysis as de-
scribed previously [38,39]. The protein content of the ly-
sates was determined using the BioRad Protein Assay
Kit (BioRad, Hercules, CA), with a BSA standard. The
antibodies against the following proteins were used for
immunoblotting: PARP-1, BCL-2, Bax, Cdk-1, Cyclin B1,
α-tubulin, β-tubulin, β-actin, acetyl-α-tubulin, HDAC6,
acetyl-H3, and Acetyl-H4 [34,35,40]. Secondary anti-
bodies were chosen according to the primary antibodies
used (goat anti-rabbit or anti- mouse IgG antibody
linked to HRP, Santa Cruz). The proteins were visualized
through the ECL system. The protein was quantified
using the β-actin protein as the loading control.
Confocal immunofluorescence
Immunostaining of cells for confocal immunofluores-
cence microscopy was done according to the published
methods [35]. Briefly the MCF and MB cells grown on
chamber slides were treated for 48 hours without or with
PEITC, the cells were then fixed, permeabilized, blocked
in BSA and incubated with a mouse anti-acetyl-α-tubulin
(Sigma-Aldrich) for 1 h. A fluorescin-conjugated goat
anti-mouse IgG was used as secondary antibody. The
DNA was counterstained with propidium iodide (PI) tovisualize the nuclei of the cells. Images were captured
using an MRC 1024 ES confocal laser scanning micros-
copy system.
Results
PEITC and taxol increased acetylation of alpha-tubulin in
breast cancer cells
Alpha-tubulin has been shown to be acetylated by HDAC6
[41]. When the cells were treated with the combination of
PEITC and taxol, the acetylation of alpha-tubulin was sig-
nificantly increased in both MCF and MB cells in compari-
son with that in single agent treated cells (Figure 1). When
the acetylation level was corrected for the amount of total
alpha-tubulin present in the specimen, there was a 16%
and 28% respective increase in the specific acetylation level
(SAL) of acetylated alpha-tubulin (acetyl-alpha-tubulin per
unit of total alpha-tubulin) in MCF cells treated with
PEITC or taxol alone (Figure 1). There was a 167% in-
crease in SAL in MCF cells treated with both PEITC and
taxol. Therefore, the combination led to a 10.4-fold and
5.96-fold increase in SAL over single agent PEITC and
taxol, respectively. This synergistic effect on acetylation of
alpha-tubulin was also seen in MB cells (Figure 1). Interest-
ingly, taxol alone also enhanced acetylation of alpha-
tubulin in both cell lines. The combination also decreased
expression of beta-tubulin more than each agent alone.
To directly visualize the activity of PEITC on breast
cancer cells in live cell culture, we next studied the level
and distribution of acetylated alpha-tubulin by immuno-
staining. The cells were visualized with confocal fluores-
cent microscopy. The cytoplasmic level of acetylated
alpha-tubulin clearly increased in both MCF and MB
cells after treatment with 5 μM of PEITC for 48 hours,
which can be directly visualized under confocal fluores-
cent microscope (Figure 2).
Effect of combination of PEITC and taxol on cyclin B1 and
CDK1 expression
Cyclin B1 and CDK1 are major cell cycle regulatory pro-
teins for the G2 to M phase progression [42]. To explore
the involvement of the major cell cycle regulatory
proteins, the level of cyclin B1 and CDK1 expression
was studied. Their expressions were characterized with
Western blotting. When compared with single agent
PEITC and taxol, the combination of both agents re-
duced the expression of CDK1 more significantly than
either agent alone (Figure 3). In the mean time, the cyc-
lin B1 expression was minimally decreased, indicating a
less significant effect from the treatment.
Effect of combination of PEITC and taxol on Bax and
Bcl-2 expression
Bax and Bcl-2 have opposing effects on apoptosis. Bax
promotes apoptosis while Bcl-2 is an anti-apoptosis
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Figure 1 Synergistic effect of phenethyl isothiocyanate (PEITC) and paclitaxel (taxol) on acetylation of alpha-tubulin and expression of
tubulins in breast cancer cells. The MCF7 cells were treated with 5 μM of PEITC and 10 nM of taxol alone or in combination. Due to higher
resistance of MDA-MB-231 cells, PEITC at 10 μM and taxol at 100 nM were used. Proteins were immunoprecipitated with appropriate antibodies
and were detected by Western blotting as described in Materials and methods. β-actin level was used as an internal loading control for protein
amount. The relative expression level over control cells was calculated after scanning of the density of each protein band with a densitometer.
A representative blot from three or more independent experiments was shown.
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cer cell lines were examined through Western blotting
analysis. When compared with single agent PEITC and
taxol, the combination of both agents reduced Bcl-2 ex-
pression and increased Bax expression more than either
agent alone (Figure 4).
Effect of combination of PEITC and taxol on PARP
cleavage
PARP proteins are important downstream components
of the apoptosis pathways. Cell cycle arrest usually trig-
gers the apoptosis machinery which leads to cellular
apoptosis and cell death. The PARP protein cleavage in






Figure 2 Acetyl-alpha-tubulin immunofluorescence in the cytoplasm
and MDA-MB-231 cells were treated with or without PEITC. The cells were
antibody was then added. The cells were visualized under confocal fluores
iodide (PI). In the treated cells, acetylated alpha-tubulin was seen in the cytsingle agent PEITC and taxol, the combination of both
agents increased the PARP-1 cleavage (thus an increase
in the degradation products as described [43]) more
than either agent alone in both cell lines (Figure 4).
Discussion
It has been shown that tubulin acetylation primarily oc-
curs on assembled microtubules [44]. PEITC has been
previously found to directly bind to alpha- and beta- tu-
bulins, thus inhibiting microtubule polymerization in
prostate cancer cells [45]. In this study, PEITC was
shown, for the first time, to induce hyperacetylation of
alpha-tubulin in two different breast cancer cell lines. It
is possible that PEITC can inhibit the synthesis of alpha-MDA-MB-231
 PEITC 10µM control
of MCF7 and MDA-MB-231 breast cancer cells. The MCF7 cells
stained with anti-acetyl-alpha-tubulin. Fluorescin-labeled secondary
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Figure 3 Combination of phenethyl isothiocyanate (PEITC) and paclitaxel (taxol) inhibits cell cycle regulator cyclin B1 and Cdk1 in
MCF7 and MDA-MB-231 breast cancer cells. The MCF7 cells were treated with 5 μM of PEI and 10 nM of taxol alone or in combination.
Due to higher resistance of MDA-MB-231 cells, PEI at 10 μM and taxol at 100 nM were used. Cyclin B1 and Cdk1 were immunoprecipitated
with appropriate antibodies and were detected by Western blotting as described in Materials and methods. β-actin level was used as an internal
loading control for protein amount. A representative blot from three or more independent experiments was shown.
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may help to explain the previous findings that some HDAC
inhibitors, such as TSA but not butyric acid, can cause
alpha-tubulin hyperacetylation [46]. This study also pro-
vided evidence to illustrate the possible mechanisms for
the synergistic anti-growth effect of PEITC and taxol to be
due to hyperacetylation of alpha-tubulin. This synergism is
best explained by the fact that taxol enhances tubulin
acetylation by inhibiting depolymerization of microtubules
and thus leads to availability of more substrates for acety-
lases, whereas PEITC decreases tubulin deacetylation.
This study also showed that the combination of PEITC
and taxol enhanced apoptosis by decreasing bcl-2 ex-
pression and by increasing BAX expression as well as
degradation of PARP. The combination of the two
agents also reduced CDK1 expression. These biochem-
ical data provided the foundation of the mechanisms for
the synergistic effects of the two agents on apoptosis
and cell cycle arrest. The similar mechanism was also
found to be responsible for PEITC inhibition of prostate
cancer cells [32,35,47-49]. Further study of this effect on
prostate cancer cells are ongoing in our laboratory.PEITC(µM)  0          5           0             5






Figure 4 Synergistic effect of phenethyl isothiocyanate (PEITC) and p
MDA-MB-231 breast cancer cells. The MCF7 cells were treated with 5 μM
resistance of MDA-MB-231 cells, PEITC at 10 μM and taxol at 100 nM were
and were detected by Western blotting as described in Materials and meth
amount. A representative blot from three or more independent experimenOur lab and others have shown that PEITC has little
toxic effects on normal cells [35,38,50]. However, taxol has
significant toxicity at higher dosage and after prolonged
use. We therefore hypothesize that by combining PEITC
and taxol, it is possible to significantly reduce toxicity
in vivo by reducing the dosage of taxol needed while main-
taining clinical efficacy for breast cancer and possibly
other solid tumors. This hypothesis will be tested first in
mouse model carrying breast cancer xenografts.
The HDAC inhibitor vorinostat has been shown to
up-regulate estrogen receptors and make breast cancer
cells more sensitive to tamoxifen [51]. HDAC inhibitor
was found to redirect the response of breast cancers
cells to tamoxifen from cell cycle arrest to apoptosis
[52]. Since PEITC is a HDAC inhibitor as well as a
tubulin-targeting agent, it would be worthwhile to test
the combination of PEITC and tamoxifen for therapy of
hormone-refractory breast cancer.
Conclusion
This study provided biochemical evidence for the mech-
anism of synergistic effect between the epigenetic agentMDA-MB-231
           0         10         0          10
          0          0         100       100
aclitaxel (taxol) on expressions of Bcl-2, Bax, PARP in MCF7 and
of PEITC and 10 nM of taxol alone or in combination. Due to higher
used. Cell lysates were immunoprecipitated with appropriate antibodies
ods. β-actin level was used as an internal loading control for protein
ts was shown.
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http://www.ehoonline.org/content/3/1/5PEITC and the chemotherapeutic agent taxol. This novel
strategy deserves further study in vivo in animal models
and may provide a new and enhanced treatment option
for breast cancer patients.
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